Association between gene polymorphisms of voltage-dependent Ca\textsuperscript{2+} channels and hypertension in the Dai people of China: a case-control study

CURRENT STATUS: ACCEPTED

BMC Medical Genetics  □ BMC Series

LiFan Huang
Institute of Medical Biology Chinese Academy of Medical Science

ORCiD: https://orcid.org/0000-0002-9821-0238

Yan Chu
Department of General Surgery of the 2nd People Hospital of Yunnan Province

Xiaoqin Huang
Institute of Medical Biology Chinese Academy of Medical Sciences

Shaohui Ma
Institute of Medical Biology Chinese Academy of Medical Sciences

Keqin Lin
Institute of Medical Biology Chinese Academy of Medical Science

Kai Huang
Institute of Medical Biology Chinese Academy of Medical Sciences

Hao Sun
sunhao@imbcams.com.cn Corresponding Author
ORCiD: https://orcid.org/0000-0003-4488-5579

Zhaoqing Yang
Institute of Medical Biology Chinese Academy of Medical Sciences

DOI: 10.21203/rs.2.19324/v2

SUBJECT AREAS
Medical Genetics

KEYWORDS
voltage-gated calcium channels, polymorphism, hypertension, Dai people
Abstract

**Background:** Abnormal calcium homeostasis related to the development of hypertension. As the key regulator of intracellular calcium concentration, voltage-gated calcium channels (VDCCs), the variations in these genes may have important effects on the development of hypertension. Here we evaluate VDCCs variability with respect to hypertension in the Dai ethnic group of China.

**Methods:** A total of 1034 samples from Dai individuals were collected, of which 495 were used as cases, and 539 were used as controls. Blood pressure was measured using a standard mercury measurement method, three times with a rest for 5 min, and the average was used for analyses. Seventeen single nucleotide polymorphisms (SNPs) in the four protein-coding genes (CACNA1A, CACNA1C, CACNA1S, CACNB2) of VDCCs were identified by multiplex PCR-SNP typing technique. Chi-square tests and regression models were used to analyse the associations of SNPs with hypertension.

**Results:** The results of chi-square tests showed that the allele frequencies of 5 SNPs were significantly different between the case and the control groups (P<0.05), but the statistical significance was lost after Bonferroni’s correction. However, after adjusting for BMI, age, sex and other factors by logistic regression analyses, the results showed that 5 SNPs consistent with chi-square tests (rs2365293, rs17539088, rs16917217, rs61839222 and rs10425859) were still statistically positive.

**Conclusions:** This finding suggested that the significant association of these SNPs with hypertension may be noteworthy in future studies.

**Introduction**

Essential hypertension (hereinafter referred to as hypertension) is now a major risk factor for stroke, cardiovascular disease and end-stage renal disease[1]. Its prevalence presented a trend of rapid increase over the past decade, especially in less developed areas. According to data from the Non-Communicable Diseases Risk Factor Collaboration (NCD-RisC), the number of adults with hypertension reached 1.13 billion in 2015[2]. In China, hypertension affects 28% of adults. A total of 82.9% of patients received treatment, but only 30% of the treated patients had their blood pressure effectively controlled[3]. Therefore, investigating the pathogenesis of hypertension for improving the prevention
and treatment of hypertension and increasing the average life span of the population is important. The relationship between hypertension and intracellular calcium concentration has been confirmed by a large number of experiments[4-7]. Therefore, changes in the function of calcium channel proteins, which have a regulatory effect on intracellular calcium concentration, may be closely related to the abnormal changes in blood pressure and the development of hypertension. Voltage-gated calcium channels (VDCCs)[8] control the entry of calcium ions into excitable cells, causing depolarization and excitation-contraction coupling of vascular smooth muscle cells (VSMCs), which not only plays an important role in regulating the concentration of calcium but also determines the contractility in VSM cells[9, 10]. Although functional experiments have supported that VDCCs can regulate blood pressure in recent years[11, 12], whether variations in the genes of VDCCs affect the function of this ion channel and the development of hypertension remains unclear.

In this study, blood samples extracted from Dai people, which natively live in Yunnan of China for centuries. As Dai people have special feelings for their land, one of their characteristics is to firmly hold their native land. Most of them live in the river valleys and flat areas surrounded by mountains. Therefore, the geographical barriers make it extremely difficult for them to communicate with groups beyond the boundary of Dai ethnic. Meanwhile, due to the closure of the society, the lack of understanding and even the estrangement with other ethnic groups, Dai people adopted the custom of intermarriage within their own group and rarely intermarried with other ethnic groups before the founding of New China. As a result, compared with other ethnic groups (such as Han), Dai people have relatively small genetic differences [13] and pathogenic spectrum among individuals.

**Material And Methods**

**Study subjects**

The study was approved by the Ethics Committee of the Institute of Medical Biology Chinese Academy of Medical Sciences, and signed informed consent from all study subjects was obtained. The samples were collected from Dai ethnic groups living in Xishuangbanna and Dehong, Yunnan, China during 2015-2018. (Each member was traced backward to the same ethnic group for three generations and is not related to other members.) Since the prevalence of hypertension is related to age, the patients
in this study were all over 40 years old (including 40 years old). The inclusion criteria of the hypertensive group were defined by the World Health Organization (1999) (systolic blood pressure (SBP) ≥140 and/or diastolic blood pressure (DBP) ≥90) or if they had previously diagnosed hypertension or were taking antihypertensive medication. Patients with renal and endocrine diseases that can cause secondary hypertension were excluded. The control group was SBP < 140 and DBP < 90, and there was no BP-lowering therapy. Blood pressure was measured using a standard mercury measurement method, three times with a rest for 5 min, and the average was used for analyses. Age, sex, body mass index (BMI), total triglyceride (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL) were recorded for all subjects. A total of 1221 patients (over 40 years old) were recruited. Considering the possibility of measurement errors, we eliminated the samples with critical values (±5 mmHg). Finally, a total of 1034 patients were included, including 495 cases and 539 controls.

**Choosing SNPs and genotyping**

Although the association analyses in the Chinese Han population[14, 15] and other countries[16, 17] suggested that the CACNA1A (rs8182538), CACNA1C (rs7581116) and the CACNB2 (rs4373814, rs11014166, rs12258967) polymorphisms were associated with blood pressure and hypertension (no reports about CACNA1S polymorphisms), these SNPs were not consistent with our pre-experimental results (200 cases vs 200 controls, unpublished results). Therefore, based on the haplotype analysis results of the Beijing Han (Chinese Han in Beijing (CHB), HapMap)[18], we chose another 17 SNPs in the genes (CACNA1A, CACNA1C, CACNA1S, CACNB2) that encode the proteins of VDCCs to perform genotyping in the Dai population. The locations of these SNPs are shown in Figure 1. There are 4 SNPs in CACNA1A, 5 SNPs in CACNA1C, 2 SNPs in CACNA1S and 6 SNPs in CACNB2. Linkage disequilibrium analysis of these SNPs was performed by Haploview software[19].

Peripheral blood (2 ml) of participants was extracted and placed into the heparin anticoagulation vacuum tube. DNA preparation: DNA extraction was performed using the AxyPrep Blood Genomic DNA Mini Prep Kit (Axygen, Hangzhou City, China) according to the manufacturer's instructions. PCR primer design: Primer 3 online version 0.4.0 was used to design specific multiple primers, which were
supplied by Shanghai Balig Biotechnology Co., Ltd. The primer sequences are shown in Supplementary Table 1. Multiplex PCR amplification was performed to obtain the PCR products (first round reaction mix for PCR contained 3.2 µl of ddH₂O, 1 µl of 10X buffer, 2 µl of 50nM primer, 0.8 µl of 2.5mM dNTP, 0.1 µl of 5U/µl Taq polymerase, 2 µl of DNA, 1 µl of 100mM Mg²⁺). Reaction system conditions included pre-denaturation 95°C for 15 min, denaturation at 94°C for 30 s, annealing at 60°C for 10 min, extension at 72°C for 30 s for 4 cycles and an extension at 72°C 30 s for 20 cycles. The second round PCR mix included 3.6 µl of ddH₂O, 2 µl of 10X buffer, 3.6 µl of 2uM barcode, 0.8 µl of 2.5mM dNTP, 0.1 µl of 5U/µl Taq polymerase, 10 µl of DNA, and 1 µl of 100mM Mg²⁺. Reaction conditions included pre-denaturation at 95°C for 15 min, denaturation at 94°C for 30 s, annealing at 60°C for 4 min, extension at 72°C for 30 s for 5 cycles and annealing at 65°C for 1 min and extension at 72°C for 30 s for 20 cycles). The Illumina HiSeq platform was used for sequencing and the sequencings were performed by Novogene Co., Ltd (Beijing, China). The sequencing images were transformed into sequenced reads through base recognition analysis, and final identification of SNPs was conducted by Samtools 0.1.19[20].

Statistical analysis

After the genotypes of the SNPs were identified, we performed statistical analyses between the case and control groups. The quantitative data were described by mean ± standard deviation, and the comparison between the two groups was performed by independent-sample T test. Qualitative data and allele frequencies were compared using the chi-square test. The associations between SNPs and hypertension were further adjusted (adjusted age, sex, BMI, TG, LDL and HDL) by logistic regression analyses in three genetic models (dominant model (AA+AB vs BB, with minor A), recessive model (AA vs AB+BB), and additive model (AA vs AB vs BB)). The T test and chi-square test were performed using SPSS 25.0 software. Logistic regression analyses were performed by plink 1.9 software[21]. Relative risk was expressed by odds ratio (OR) and 95% CI. All statistical tests were statistically significant with two-tailed probability (P<0.05).

Results

General subject information
The basic characteristics of the case and the control groups, which contain 495 hypertensive patients and 539 normal blood pressure controls, are shown in Table 1. Sex, age, BMI, TG, LDL, HDL, SBP and DBP were recorded and evaluated. The chi-square test was used for sex, and other quantitative data were compared using the independent-sample T test. There was no significant difference in sex and HDL between the case and the control groups, but age, BMI, TG and LDL suggested that the occurrence of hypertension was affected by complex factors.

**SNPs typing and analyses**

All samples were typed by multiplex PCR-SNP technology. The call rate of genotyping of all SNPs was more than 90%. The frequency distributions of all 17 SNPs were in Hardy Weinberg Equilibrium (HWE) in both the cases and controls (P>0.003, 0.05/17). The chi-square tests (Table 2) were used to compare the allelic frequency of 17 SNPs on 4 genes in the cases and the controls. There was no significant difference in the CACNA1C gene between the cases and the controls. One SNP in CACNA1S, three SNPs in CACNB2 and one SNP in CACNA1A showed significant differences between the case and the control groups. However, after Bonferroni’s correction (P<0.003 (0.05/17)), the results were not significant.

**Logistic regression analysis of association with hypertension**

Given that Bonferroni's correction was too strict, we introduced covariables (adjusted sex, age, BMI, TG, LDL, and HDL) into logistic regression models to adjust the association between polymorphisms and hypertension. Regression analyses (Table 3) were performed under the assumption of three genetic models (dominant, recessive and additive models) for 5 SNPs, which showed significant differences in chi-square tests. The significant associations were found between under the assumption of the dominant model (four SNPs) and the additive model (four SNPs), but no SNPs in the recessive model.

**Discussion**

Although the statistically significant SNPs were no longer significant after Bonferroni’s correction, logistic regression still suggested that 5 candidate SNPs consistent with the chi-square tests were associated with hypertension (adjust sex, age, BMI, TG, LDL, and HDL).
VDCCs mediate the entry of calcium ions into excitable cells. Their function involves the contraction of vascular smooth muscle, the release of neurotransmitters or hormones and the expression of genes. The VDCC is a multi-protein complex composed of a variety of subunits, including α1, β, α2/δ and γ. The activity of VDCCs is mainly directed by the pore-forming α1 subunit, which is the target of calcium antagonist (CCBs)[22, 23], and can be divided into different types, such as α1A, α1B, α1C, α1D, α1E and α1S. In this study, the SNPs selected from the genes encoded subunits alpha 1A (CACNA1A), alpha 1C (CACNA1C), alpha 1S (CACNA1S), and beta (CACNB2).

Previous studies have shown that the upregulation of VDCC expression can lead to the enhancement of calcium influx and thereby increase the contractility of VSMCs[24], which partly explains the pathogenesis of hypertension. On the other hand, VDCCs not only regulate the contraction of VSMCs but also affect differentiation, which is also associated with various cardiovascular diseases[25]. Kudryavtseva O et al[26] investigated the effect of VDCCs on VSMC differentiation by injecting alpha 1C-siRNA into mice to reduce the expression of VDCCs. Their research showed that the decrease in VDCC expression promoted the change in VSMCs from contractile to non-contractile (the mRNA expression of myosin heavy chain 11 (Myh11), α-actin (Acta2), h-caldesmon was significantly reduced). Therefore, whether the upregulation or downregulation of VDCC expression can cause a change in VSMC tone.

We found one positive SNP (rs10425859), which suggest an increased risk for the people carried the A\textsubscript{minor} allele on this SNP. (OR\textsubscript{Additive} = 1.269 CI95%\textsubscript{Additive} = 1.030-1.563), in CACNA1A in the Dai population after logistic regression analyses, in CACNA1A in the Dai population after logistic regression analyses. The α1A (CACNA1A) subunit is mainly expressed in the nervous tissue of the brain and involves the transmission of synaptic signals in the central nervous system. Research on rat models has shown that abnormal expression of the CACNA1A gene can lead to the desensitization of calcitonin gene-related peptide (CGRP) receptors, which are critical in maintaining the systolic response of cerebrovascular smooth muscle[27, 28]. In addition, Hu Z et al. also reported the association between CACNA1A polymorphisms (rs8182538) and hypertension in Chinese Han[15]. In Dai people, another positive SNP (rs2365293), which suggest an increased risk for the people
carried the $T_{\text{minor}}$ allele on this SNP ($\text{OR}_{\text{Dominant}} = 1.335 \text{ CI95\%}_{\text{Dominant}} = 1.002-1.778$). It was found in CACNA1S, which encodes the $\alpha_{1S}$ subunit expressed in skeletal muscle cells. According to the database of Online Mendelian Inheritance in Man (OMIM), the mutations in this gene are associated with hypokalemic periodic paralysis, thyrotoxic periodic paralysis, and malignant hyperpyrexia. A report has shown that this gene is associated with hypertension in genome-wide homozygous imbalance analysis,[29] but the specific mechanism of hypertension has not been reported. Association analyses in China[14], Lithuanian[17] and Europe[16] have reported the association between CACNB2 polymorphisms (rs4373814 in Chinese Han, rs12258967 in Lithuanian and rs18748804 in Europe) and hypertension. In our study, we found three other positive SNPs (rs17539088, $G_{\text{minor}}, \text{ OR}_{\text{Dominant}} = 0.732 \text{ CI95\%}_{\text{Dominant}} = 0.554-0.966, \text{ OR}_{\text{Additive}} = 0.769$

$\text{CI95\%}_{\text{Additive}} = 0.616-0.960; \text{ rs16917217, G}_{\text{minor}}, \text{ OR}_{\text{Dominant}} = 0.737 \text{ CI95\%}_{\text{Dominant}} = 0.558-0.973, \text{ OR}_{\text{Additive}} = 0.776 \text{ CI95\%}_{\text{Additive}} = 0.622-0.969; \text{ and rs61839222}, A_{\text{minor}}, \text{ OR}_{\text{Dominant}} = 0.737 \text{ CI95\%}_{\text{Dominant}} = 0.558-0.973, \text{ OR}_{\text{Additive}} = 0.776 \text{ CI95\%}_{\text{Additive}} = 0.622-0.969$), which suggest a decreased risk, in CACNB2 after logistic regression analyses. Although the auxiliary subunit coded by CACNB2 is not the main structure of VDCC activity, it is equally important to maintain the normal structure and function of the whole protein complex. For example, the molecular signals released by the $\beta$ subunit guide $\alpha1$ subunit transport to the plasma membrane to construct the correct functional protein complex[30]. In addition, Durairaj Pandian V et al. found that the overexpression of CACNB2 can upregulate the gene expression of the RAS-MAPK pathway, which is one of the key chain reactions of hypertension[31].

The identification of pathogenic genes of complex diseases such as hypertension has always been difficult. Generally, association analyses are used to screen risk genetic variations of complex diseases. One of the difficulties in association research is that the genetic background of the samples used in the analysis is complex. Due to ethnic and cultural habits, most Dai people are likely to inhabit their villages and rarely intermarry with other ethnic groups in Yunnan Province, leading to the relatively homogenous genetic background of the Dai people. Compared with the Han people who
have a complex genetic heterogeneity, the Dai have a genetical homogeneity and smaller pool of susceptibility genes. The disease gene spectrum of hypertension may be narrow in this population. A few disease gene mutations responded for the hypertension in Dai people, which provides an advantage in finding susceptibility variations of hypertension in this special group. The positive SNPs showed in this study all locate in the intron. These SNPs may be linked to susceptible mutations, which make them show positive results in association analysis. The frequency of susceptible mutations may be low, so it is difficult to obtain significant positive results by association analysis. However, during evolution, especially in these ethnic groups with a relatively narrow genetic background, the mutations are likely to be linked to Tag SNPs, so that they can be detected in our study. These findings may help us understand the genetic causes of hypertension from a unique perspective.

There are some limitations in the current study. First, as a cross-sectional study, we were not able to determine the causal relationship between VDCCs and hypertension. Second, since all the participants were Dai people, the generalisability of the results may not extend to non-Dai populations. Although the main constraint of this study was the small sample size of the Dai group, the statistical power is enough for the number of analysed SNPs. Further functional studies and association analyses in larger samples and other populations should be conducted to confirm our results.

Conclusion
In this study, the SNPs identified in the CACNA1S, CACNB2 and CACNA1S genes suggest a different molecular pathogenesis of hypertension in Dai people. Therefore, further studies are needed to verify the functional association between variations in VDCC protein-coding genes and hypertension and susceptibility to hypertension in terms of ethnicity, which may help develop new hypertension diagnoses and treatment methods.

Declarations

Ethics approval: The study was approved by the Ethics Committee at the Institute of Medical Biology Chinese Academy of Medical Sciences.
Availability of data and materials: All data generated or analysed during this study are included in this published article [and its supplementary information files].

Competing Interests: All the authors have approved the manuscript and agree with submission, and have no conflicts of interest to declare.

Funding: National Natural Science Foundation of China No. 31571304; Yunnan Basic Research Program Key Project No. 2018FA010.

Authors' contributions: LFH and HS contributed to the conception or design of the work. HS, YC, XQH and ZQY contributed to the acquisition, analysis or interpretation of data for the work. SHM and KQL drafted the manuscript. KH critically revised the manuscript. All authors gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

Acknowledgments: The authors gratefully acknowledge the research grants that supported this study, including National Natural Science Foundation of China No. 31571304 to HS. Yunnan Basic Research Program Key Project No. 2018FA010 to HS.

Consent for publication: Parental/guardian consent obtained

Abbreviations
VDCCs: Voltage-gated calcium channels
SNPs: Single nucleotide polymorphisms
NCD-RisC: Non-Communicable Diseases Risk Factor Collaboration
VSMCs: Vascular smooth muscle cells
SBP: Systolic blood pressure
DBP: Diastolic blood pressure
CHB: Chinese Han in Beijing
BMI: Body mass index
TG: Total triglyceride
LDL: Low density lipoprotein
HDL: High density lipoprotein
OR: odds ratio
Cl: confidence interval
HWE: Hardy Weinberg Equilibrium
Myh11: Myosin heavy chain 11
CGRP: Calcitonin gene-related peptide
OMIM: Online Mendelian Inheritance in Man

References

1. Lackland DT, Weber MA: Global burden of cardiovascular disease and stroke: hypertension at the core. The Canadian journal of cardiology 2015, 31(5):569-571.

2. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet (London, England) 2017, 389(10064):37-55.

3. Li Y, Yang L, Wang L, Zhang M, Huang Z, Deng Q, Zhou M, Chen Z, Wang L: Burden of hypertension in China: A nationally representative survey of 174,621 adults. Int J Cardiol 2017, 227:516-523.

4. Behuliak M, Bencze M, Vaneckova I, Kunes J, Zicha J: Basal and Activated Calcium Sensitization Mediated by RhoA/Rho Kinase Pathway in Rats with Genetic and Salt Hypertension. Biomed Res Int 2017, 2017:8029728.

5. Zhu Y, Qu J, He L, Zhang F, Zhou Z, Yang S, Zhou Y: Calcium in Vascular Smooth Muscle Cell Elasticity and Adhesion: Novel Insights Into the Mechanism of Action. Frontiers in physiology 2019, 10:852.

6. Tocci G, Battistoni A, Passerini J, Musumeci MB, Francia P, Ferrucci A, Volpe M: Calcium channel blockers and hypertension. Journal of cardiovascular pharmacology and therapeutics 2015, 20(2):121-130.

7. Sowers JR, Zemel MB, Standley PR, Zemel PC: Calcium and hypertension. The Journal of laboratory and clinical medicine 1989, 114(4):338-348.

8. Dolphin AC: Voltage-gated calcium channels: their discovery, function and
importance as drug targets. *Brain and neuroscience advances* 2018, 2.

9. Richard S, Perrier E, Fauconnier J, Perrier R, Pereira L, Gomez AM, Benitah JP: 'Ca(2+)-induced Ca(2+) entry' or how the L-type Ca(2+) channel remodels its own signalling pathway in cardiac cells. *Progress in biophysics and molecular biology* 2006, 90(1-3):118-135.

10. Thuesen AD, Lyngso KS, Rasmussen L, Stubbe J, Skott O, Poulsen FR, Pedersen CB, Rasmussen LM, Hansen PB: P/Q-type and T-type voltage-gated calcium channels are involved in the contraction of mammary and brain blood vessels from hypertensive patients. *Acta physiologica (Oxford, England)* 2017, 219(3):640-651.

11. de Pascual R, Miranda-Ferreira R, Galvao KM, Lameu C, Ulrich H, Smaili SS, Jurkiewicz A, Garcia AG, Gandia L: Lower density of L-type and higher density of P/Q-type of calcium channels in chromaffin cells of hypertensive, compared with normotensive rats. *Eur J Pharmacol* 2013, 706(1-3):25-35.

12. Hansen PB, Poulsen CB, Walter S, Marcussen N, Cribbs LL, Skott O, Jensen BL: Functional importance of L- and P/Q-type voltage-gated calcium channels in human renal vasculature. *Hypertension* 2011, 58(3):464-470.

13. Sun H, Zhou C, Huang X, Liu S, Lin K, Yu L, Huang K, Chu J, Yang Z: Correlation between the linguistic affinity and genetic diversity of Chinese ethnic groups. *J Hum Genet* 2013, 58(10):686-693.

14. Hong GL, Chen XZ, Liu Y, Liu YH, Fu X, Lin SB, Zhu Q: Genetic variations in MOV10 and CACNB2 are associated with hypertension in a Chinese Han population. *Genetics and molecular research : GMR* 2013, 12(4):6220-6227.

15. Hu Z, Liu F, Li M, He J, Huang J, Rao DC, Hixson JE, Gu C, Kelly TN, Chen S et al: Associations of Variants in the CACNA1A and CACNA1C Genes With Longitudinal Blood Pressure Changes and Hypertension Incidence: The
**GenSalt Study.** *Am J Hypertens* 2016, **29**(11):1301-1306.

16. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson AD, Aspelund T et al: **Genome-wide association study of blood pressure and hypertension.** *Nat Genet* 2009, **41**(6):677-687.

17. Simonyte S, Kuciene R, Dulskiene V, Lesauskaite V: **Association between ATP2B1 and CACNB2 polymorphisms and high blood pressure in a population of Lithuanian children and adolescents: a cross-sectional study.** *BMJ open* 2018, **8**(7):e019902.

18. **A haplotype map of the human genome.** *Nature* 2005, **437**(7063):1299-1320.

19. Barrett JC: **Haploview: Visualization and analysis of SNP genotype data.** *Cold Spring Harbor protocols* 2009, **2009**(10):pdb.ip71.

20. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R: **The Sequence Alignment/Map format and SAMtools.** *Bioinformatics (Oxford, England)* 2009, **25**(16):2078-2079.

21. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ et al: **PLINK: a tool set for whole-genome association and population-based linkage analyses.** *Am J Hum Genet* 2007, **81**(3):559-575.

22. Tang L, Gamal El-Din TM, Lenaeus MJ, Zheng N, Catterall WA: **Structural Basis for Diltiazem Block of a Voltage-Gated Ca(2+) Channel.** *Molecular pharmacology* 2019, **96**(4):485-492.

23. Tang L, Gamal El-Din TM, Swanson TM, Pryde DC, Scheuer T, Zheng N, Catterall WA: **Structural basis for inhibition of a voltage-gated Ca(2+) channel by Ca(2+) antagonist drugs.** *Nature* 2016, **537**(7618):117-121.

24. Pratt PF, Bonnet S, Ludwig LM, Bonnet P, Rusch NJ: **Upregulation of L-type Ca2+ channels in mesenteric and skeletal arteries of SHR.** *Hypertension* 2002,
25. Kumar MS, Owens GK: **Combinatorial control of smooth muscle-specific gene expression.** *Arteriosclerosis, thrombosis, and vascular biology* 2003, **23**(5):737-747.

26. Kudryavtseva O, Herum KM, Dam VS, Straarup MS, Kamaev D, Briggs Boedtkjer DM, Matchkov VV, Aalkjaer C: **Downregulation of L-type Ca2+ channel in rat mesenteric arteries leads to loss of smooth muscle contractile phenotype and inward hypertrophic remodeling.** *American journal of physiology Heart and circulatory physiology* 2014, **306**(9):H1287-1301.

27. Chan KY, Labastida-Ramirez A, Ramirez-Rosas MB, Labruijere S, Garrelds IM, Danser AH, van den Maagdenberg AM, MaassenVanDenBrink A: **Trigeminovascular calcitonin gene-related peptide function in Cacna1a R192Q-mutated knock-in mice.** *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism* 2019, **39**(4):718-729.

28. Wang Z, Martorell BC, Walchli T, Vogel O, Fischer J, Born W, Vogel J: **Calcitonin gene-related peptide (CGRP) receptors are important to maintain cerebrovascular reactivity in chronic hypertension.** *PLoS One* 2015, **10**(4):e0123697.

29. Yang HC, Li HW: **Analysis of homozygosity disequilibrium using whole-genome sequencing data.** *BMC proceedings* 2014, **8**(Suppl 1 Genetic Analysis Workshop 18Vanessa Olmo):S15.

30. Striessnig J, Pinggera A, Kaur G, Bock G, Tuluc P: **L-type Ca(2+) channels in heart and brain.** *Wiley interdisciplinary reviews Membrane transport and signaling* 2014, **3**(2):15-38.

31. Durairaj Pandian V, Giovannucci DR, Vazquez G, Kumarasamy S: **CACNB2 is associated with aberrant RAS-MAPK signaling in hypertensive Dahl Salt-
**Sensitive rats. Biochem Biophys Res Commun 2019, 513(3):760-765.**

Tables

Table 1: Survey indicators and statistical analysis of the study participants.

|                                      | Hypertensive | Normal  | p      |
|--------------------------------------|--------------|---------|--------|
| number of people                     | 495          | 539     |        |
| sex (male/female)                    | 199/296      | 186/353 | 0.059  |
| age (years)                          | 60.01±10.68  | 53.37±10.36 | <0.001* |
| BMI (kg/m²)                          | 23.88±3.12   | 22.76±3.12 | <0.001* |
| systolic blood pressure (mmHg)       | 164.86±20.22 | 117.94±10.38 | <0.001* |
| diastolic blood pressure (mmHg)      | 94.48±12.50  | 72.79±7.382 | <0.001* |
| total triglycerides (mmol/L)         | 2.24±1.67    | 1.82±1.81 | <0.001* |
| low density lipoprotein (mmol/L)     | 2.83±0.83    | 2.56±0.75 | <0.001* |
| high density lipoprotein (mmol/L)    | 1.43±0.47    | 1.42±0.31 | 0.960  |

Quantitative data are reported as the mean ± standard deviation and were tested with the independent-sample T test. Qualitative data were analysed by the chi-square test. *P < 0.05. BMI = body mass index.

Table 2: Comparison of the 17 SNP frequencies between hypertensive and normal populations

| Nearby gene | SNP       | Chromosome: position | Minor/Major | Hypertensive | Normal  | P      |
|-------------|-----------|----------------------|-------------|--------------|---------|--------|
| CACNA1S     | rs3767505 | 1:201065408          | C/T         | 272/658      | 326/712 | 0.298  |
|             | rs2365293 | 1:201106117          | T/C         | 335/561      | 332/678 | 0.039* |
| CACNB2      | rs10764327| 10:18159919          | G/T         | 350/526      | 427/601 | 0.484  |
|             | rs1757209 | 10:18183913          | G/A         | 149/775      | 203/841 | 0.055  |
|             | rs7072759 | 10:18282286          | G/A         | 404/494      | 446/570 | 0.632  |
|             | rs17539088| 10:18370214          | G/A         | 270/676      | 343/691 | 0.026* |
|             | rs16917217| 10:18370276          | G/A         | 274/678      | 343/689 | 0.032* |
|             | rs61839222| 10:18370285          | A/C         | 274/678      | 343/689 | 0.032* |
| CACNA1C     | rs2283274 | 12:2075300           | C/G         | 323/591      | 366/652 | 0.779  |
|             | rs7304870 | 12:2164089           | A/G         | 448/422      | 498/528 | 0.200  |
|             | rs10848627| 12:2203242           | G/A         | 296/654      | 343/703 | 0.435  |
|             | rs10848628| 12:2203323           | C/T         | 291/657      | 341/701 | 0.331  |
|             | rs2239031 | 12:2227003           | T/G         | 262/680      | 304/734 | 0.469  |
| CACNA1A     | rs2074880 | 19:13261817          | C/A         | 353/557      | 436/580 | 0.066  |
|             | rs10425859| 19:13408848          | A/G         | 469/461      | 474/562 | 0.038* |
|             | rs76143985| 19:13415178          | A/G         | 268/650      | 265/777 | 0.062  |
|             | rs1422259 | 19:13428788          | C/T         | 293/627      | 337/679 | 0.535  |

The chi-square test was performed for the 17 loci in the Dai group. SNP = single nucleotide polymorphism. *P < 0.05, but after Bonferroni’s correction (P<0.003 (0.05/17)), the positive results disappeared.
Table 3: Relation of SNPs to hypertension as determined by multivariable logistic regression analysis

| Nearby gene | SNP     | Minor/Major | P   | OR (95% CI) | OR (95% CI) | OR (95% CI) | P   |
|-------------|---------|-------------|-----|-------------|-------------|-------------|-----|
|             |         | Dominant    |     |             | Recessive   | Additive    |     |
| CACNA1S     | rs2365293| T/C         | 0.048* | 1.3351-1.778 | 1.102       | -           | 0.093 |
| CACNB2      | rs17539088| G/A         | 0.027* | 0.7320-0.966 | 0.702       | -           | 0.021* |
|             | rs16917217| G/A         | 0.031* | 0.7370-0.973 | 0.719       | -           | 0.025* |
|             | rs61839222| A/C         | 0.031* | 0.7370-0.973 | 0.719       | -           | 0.025* |
| CACNA1A     | rs10425859| A/G         | 0.177  | -           | 1.494       | -           | 0.025* |

Multivariable logistic regression analysis was performed with adjustment for sex, age, BMI, TG, LDL and HDL. OR, odds ratio; CI, confidence interval.

Figures
Figure 1

Locations of the 17 SNPs at the VDCC coding-gene locus and their haplotype configurations.

The values shown in these haploblock figures are all r2 in Dai people.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
Supplementary Table 1 .docx